CLMTCalumet, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~23% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 17.6× across 53 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CLMT's price assumes
Calumet, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.94× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.4%
Free cash flow yield · Specialty Chemicals median 4.8%
- Growth the price implies
- +23%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- EV / sales
- 1.41
EV / sales
Details›
- EV / EBIToperating margin 1.0%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.41
- Free cash flow, trailing twelve months
- $58M
- Market capitalisation87.9 million shares, counted Aug 7, 2026
- $4.34B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.